On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2016: Volume 21/ Issue 1 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 21, Issue 1, 07 January 2016
Eurosurveillance editorial team: The year past and the year ahead – some facts and figures about Eurosurveillance

+ Author affiliations

Citation style for this article: Eurosurveillance editorial team. The year past and the year ahead – some facts and figures about Eurosurveillance. Euro Surveill. 2016;21(1):pii=30098. DOI:

The year 2016 marks the 20th year in which Eurosurveillance has been published regularly. And there are good news for the journal’s contributors and supporters. Eurosurveillance has remained among the top 10 journals in its field in science citation index since it was awarded its first impact factor for the year 2011. Feedback indicates that the journal has a reputation for publishing an interesting mix of public health-relevant and scientific articles to serve its diverse audiences.

Looking back at the year 2015, the wide range of topics included matters that were high on the public health agenda: communicable diseases in connection with the refugee crisis, the Ebola outbreak in West Africa, the Middle East Respiratory Syndrome (MERS) coronavirus epidemic and the largest MERS outbreak outside the Arabian Peninsula shaking the Korean health system, influenza vaccine effectiveness in a season with antigenic mismatch between circulating and vaccine A(H3N2) viruses, and antimicrobial resistance – in particular carbapenemase-producing Gram-negative multidrug-resistant organisms and emergence of colistin resistance. We also dedicated a special issue to HIV and sexually transmitted infections with a focus on epidemiology, prevention and control among men who have sex with men in Europe [1].

We continue with a mix of topics also in the first issue of 2016. It features a rapid communication on cholera importation from the Philippines which serves as reminder to consider this in advice for travellers to endemic areas other than Haiti and Africa [2]. Another rapid communication reports the likely establishment of schistosomiasis in the Canu River on Corsica and its implications [3]. Furthermore, an article from New Zealand on the influenza vaccine effectiveness from the most recent influenza season in the southern hemisphere gives some indication for what might be expected during the ongoing season in the northern hemisphere [4].

As is our tradition at the beginning of every year, we publish a list with the names of peer reviewers who supported us in the past year [5]. We are grateful to some 530 experts who dedicated their time and reviewed for us in 2015. Their thoughts and expertise are invaluable for our decision-making. We are also guided times and again by our board and a wholehearted ‘Thank you’ goes to our associate editors and editorial advisors for this. Other supporters and colleagues who help us and who are often partners for testing ideas remain unnamed here, still we would like to thank them warmly and hope to be able to count on them also in 2016. We are grateful for continued funding, logistic support and encouragement from our publisher the European Centre for Disease Prevention and Control (ECDC) who grants us the editorial freedom we need to work according to the scientific standards we aspire.

With all this support, Eurosurveillance fared well. The impact factor for 2014, released in 2015, is at 5.7 (4.6 in 2013) and the journal is well positioned also in other metrics such as those provided by SCImago and Google scholar. The editorial office received on average 64 submissions per month. Of the total 770 articles submitted in 2015 (491 regular, 240 rapid communications, 39 other), we selected for peer-review those that we deemed of most interest for our readers. The rejection rate currently stands at around 73%, i.e. ca one in four submissions will make it to publication. The geographical origin of our submissions showed a worldwide distribution also in 2015. A number of articles from outside of Europe were accepted for publication while the bulk of published work was from Europe and published articles generally are of European relevance.

From January 2016 onwards, two new associate editors, Professor Magnus Boman, Royal Institute of Technology, Stockholm, Sweden and Professor Jacob Moran-Gilad, Ben-Guirion University, Beer-Sheva, Israel, have joined the editorial board as associate editors. They will complement the strength of the present group with their respective expertise as computational epidemiologist and clinical microbiologist, and in public health.

Success and recognition of a journal come with better visibility and more attention. Scientists in academia and public health are under pressure to publish in journals with a solid impact factor to advance their careers. Timely publication, authorship and data ownership are highly relevant. Publication ethics have been on the editors’ agenda for many years and in the resolution of complaints, appeals and requests for authorship changes we have followed available guidance from the Committee on Publication Ethics (COPE, In 2015, we invited a council member of COPE to give a presentation at our board meeting. To inform our contributors and readers about our procedures, we recently published policies on appeals and complaints and on changes in authorship on our website.

Eurosurveillance has always been an open access journal and from the beginning of 2016, articles will be published under a Creative Commons Attribution (CC BY) licence and authors retain the copyright. Readers are free to share and adapt the published material, but must give appropriate credit, provide a link to the licence, and indicate if changes were made. They may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or the use.

Every year comes with new challenges and surprises. We are looking forward to what 2016 will bring. We are confident that together with our board members, authors, supporters and readers, we will face the new challenges and continue to provide timely and important data for public health action and evidence for policymaking. In November, we will celebrate the 20th anniversary of Eurosurveillance at our scientific seminar on the margins of the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) in Stockholm.


  1. Eurosurveillance. Special edition: HIV in MSM. June2015. Stockholm: Eurosurveillance. [Accessed 7 Jan 2016]. Available from:

  2. Slesak G, Fleck R, Jacob D, Grunow R, Schäfer J. Imported cholera with acute renal failure after a short business-trip to the Philippines, Germany, October 2015.Euro Surveill. 2016;21(1):30099. DOI: 10.2807/1560-7917.ES.2016.21.1.30099

  3. Berry A, Fillaux J, Martin-Blondel G, Boissier J, Iriart X, Marchou B,  et al.  Evidence for a permanent presence of schistosomiasis in Corsica, France, 2015. Euro Surveill. 2016;21(1):30100. DOI: 10.2807/1560-7917.ES.2016.21.1.30100

  4. Bissielo A, Pierse N, Huang Q, Thompson M, Kelly H, Mishin V,  et al.  Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. Euro Surveill. 2016;21(1):30101. DOI: 10.2807/1560-7917.ES.2016.21.1.30101

  5. Eurosurveillance editorial team. Eurosurveillance reviewers in 2015.Euro Surveill. 2016;21(1):30102. DOI: 10.2807/1560-7917.ES.2016.21.1.30102

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.